1.What is targeted therapy? Targeted therapy, that is, at the level of cellular molecules, targets the abnormal molecules or genes (targets) in tumorigenesis and designs the corresponding therapeutic drugs, which will specifically act on the target when entering the body and cause the tumor cells to specifically die without affecting the normal tissue cells around the tumor. 2.Does targeted therapy work well? Targeted therapy can make the drug target tumor cells more specifically, save relatively high concentration in tumor local area and prolong the time of the drug, so as to improve the killing effect on tumor, but less on normal tissue cells, so the efficacy is more prominent than conventional chemotherapy and the toxic side effects are relatively light. 3. Under what circumstances is targeted therapy suitable? Targeted therapy should firstly detect whether there is an abnormal molecular or genetic target, and secondly, there should be a therapeutic drug for that target, if these two conditions can be met at the same time, then targeted therapy can be implemented. Of course, there are also certain requirements for patients’ physical condition, such as liver and kidney function, heart function, etc. 4.The difference between targeted therapy and conventional chemotherapy? The biggest difference between targeted drugs and conventional chemotherapy drugs lies in their mechanism of action: conventional chemotherapy drugs work by killing actively growing cells, but they cannot accurately identify tumor cells, so while killing tumor cells, they will also affect normal cells, so they have greater toxic side effects. In contrast, targeted drugs are developed for abnormal molecules and genes of tumors, which can combine with abnormal targets specific to tumor cells or tissues to kill tumor cells or stop their growth, due to such characteristics, targeted drugs are not only effective, but also have much less side effects than conventional chemotherapy methods. Anti-tumor drugs can affect both normal cells and tumor cells when they enter the body. Although both types of cells can die due to irreversible cell damage caused by chemotherapy drugs, normal cells have stronger repair ability and can continue to survive if the damage is small. Targeted therapy only targets tumor cells with altered characteristics, which reduces the damage to normal cells while exerting stronger anti-tumor activity. Therefore, clinically, targeted therapy is less likely to cause a series of toxic side effects caused by chemotherapy drugs. 5.Is targeted therapy mature at present? With Herceptin becoming the first targeted drug approved for use (breast cancer) in 1998, and the first anti-tumor monoclonal antibody, and Gleevec being the first small molecule targeted drug approved for use in gastrointestinal mesenchymal tumor in 2002, targeted therapy has been rapidly developing in clinical application through more than ten years of development, and has become more and more mature, and its efficacy has become more and more certain. Now, such as Meroval applied to CD20-positive lymphoma, Eressa (Gefitinib) and Troche (Erlotinib) for the treatment of advanced non-small cell lung cancer, Sotan for kidney cancer, neuroendocrine tumors, mesenchymal tumors, bevacizumab and cetuximab for colorectal cancer, etc., several targeted drugs have been approved for clinical indications, bringing gospel to many patients. 6.What is the classification of targeted therapeutic drugs? With the in-depth research on molecular targets for solid tumor treatment, it is now possible to inhibit these targets through various pathways. ; (2) the other is the use of small molecule inhibitors that directly enter the cell to close the receptor and interfere with the intracellular signaling, such as Gleevec and Erysal.